The company is developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation.

Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s  Board of Directors. 

Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company, which is developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation.

“Tom is a highly strategic, deeply experienced biotech executive, and I’m delighted to be working with him again,” stays Natalie Holles, chief executive officer of Third Harmonic Bio, in a news release. “Tom’s perspective on company building and capital formation will be invaluable as we scale the company and embark on our clinical trial of THB-001 for the treatment of chronic urticaria in the second half of this year.”

Mr. Soloway is currently chief executive officer of T-knife Therapeutics, Inc. Before joining T-knife, he was at Audentes Therapeutics, Inc., most recently serving as executive vice president and chief operating officer. Previously, Mr. Soloway served as senior vice president and chief financial officer of Ascendis Pharma A/S. Prior to Ascendis,  Mr. Soloway co-founded Transcept Pharmaceuticals, Inc., where he served as executive vice president and chief operating officer. Before Transcept, Mr. Soloway was a principal at Montreux Equity Partners, a venture capital firm focused on providing growth capital for early-stage healthcare and life sciences companies. Mr. Soloway holds a B.S. in entrepreneurial studies from the University of Southern California and an M.B.A. from Georgetown University.

 “With “pipeline-in-a-product” potential of THB-001, we have the opportunity to impact the lives of millions of patients living with severe allergy and inflammation, including dermal, respiratory and gastrointestinal diseases, conditions which can take a significant toll on health and well-being,” says Mr. Soloway. “I am excited to be working closely with the board and management team as we set out to advance the next wave of medicines in high unmet need allergy and inflammation indications.”

About THB001

THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. The company has completed a Phase 1a clinical trial in healthy volunteer for THB001 and anticipates initiating a Phase 1b proof-of-concept study in chronic inducible urticaria during the second half of 2022. With promising drug-like properties and an encouraging early clinical profile, THB001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory and gastrointestinal allergic and mast-cell-mediated inflammatory diseases.